Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 665 participants.
Also called NCT01631227
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 665 participants
- Sponsor
- Registry
-
NCT01631227 -
2010-019432-12
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany, Russia, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01631227. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-05-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Eprosartan
- Intervention (Drug)
- Eprosartan Mesylate
- Intervention (Drug)
- Placebo Eprosartan mesylate
- Intervention (Drug)
- Placebo Eprosartan
- Lead sponsor
- Abbott
- Collaborator
- Quintiles, Inc.
- Collaborator
- Synexus
- Collaborator
- author! et al. BV
Record details
- Record id
cardio:ct-nct01631227- Content hash
36ae24da9ea51654362bd034ebd9a4d9daa317f0a3ea87e80e0d0acab6f9acfe